An agent for the prevention and treatment of inflammatory bowel disease (IBD) containing at least one of zinc L-carnosine salts and complexes as an active ingredient. A use of the zinc L-carnosine salts or complexes and a therapeutic method of IBD by using the same are also disclosed.

Zeria Pharmaceutical Co., Ltd.

Hamari Chemicals, Ltd.

Inflammatory bowel disease preventive and curative agent containing zinc L-carnosine salt as active ingredient

A method for treating an autism spectrum condition includes administering an effective dose of a TNF-.alpha. inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-.alpha. in the cerebrospinal fluid or elevated TNF-.alpha. in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-.alpha. in the cerebrospinal fluid or elevated TNF-.alpha. in the serum. A TNF-.alpha. inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.

Chez; Michael

Agent and methods for reducing inflammatory markers

In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines.

LivePet, LLC

Cellular enhancements in biological systems through the use of li-pofullerene and peptide group combinations

Compositions and methods for the treatment and prevention of at least one of a sign and a symptom associated with an eye disease are disclosed. Preferred compositions could comprise a liquid formulation including Cineraria maritima and at least one of a nonsteroidal anti-inflammatory drug, a carnosine, and a cannabinoid.

carnosine/inflammation

Inflammatory bowel disease preventive and curative agent containing zinc L-carnosine salt as active ingredient

Agent and methods for reducing inflammatory markers

Cellular enhancements in biological systems through the use of li-pofullerene and peptide group combinations

Methods and compositions for treating and preventing signs or symptoms of eye disease

科学支持的最完整的草药数据库